1159706-00-9

Basic information

• Product Name: [6S,9R,11R]-2',3',4',5,5',6,7,8,9,10-decahydro-2-([2-(4-fluorophenyl)-2-oxoethyl]carboxamido)-5'-(2,2,2-trifluoroethyl)-spiro[6,9-methanobenzocyclooctene-11,3'-[1,2,5]thiadiazole] 1',1'-dioxide
• Synonyms: [6S,9R,11R]-2',3',4',5,5',6,7,8,9,10-decahydro-2-([2-(4-fluorophenyl)-2-oxoethyl]carboxamido)-5'-(2,2,2-trifluoroethyl)-spiro[6,9-methanobenzocyclooctene-11,3'-[1,2,5]thiadiazole] 1',1'-dioxide
• CAS NO: 1159706-00-9
• Molecular Weight: 539.551
• Mol File: 1159706-00-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: [6S,9R,11R]-2',3',4',5,5',6,7,8,9,10-decahydro-2-([2-(4-fluorophenyl)-2-oxoethyl]carboxamido)-5'-(2,2,2-trifluoroethyl)-spiro[6,9-methanobenzocyclooctene-11,3'-[1,2,5]thiadiazole] 1',1'-dioxide(CAS DataBase Reference)
• NIST Chemistry Reference: [6S,9R,11R]-2',3',4',5,5',6,7,8,9,10-decahydro-2-([2-(4-fluorophenyl)-2-oxoethyl]carboxamido)-5'-(2,2,2-trifluoroethyl)-spiro[6,9-methanobenzocyclooctene-11,3'-[1,2,5]thiadiazole] 1',1'-dioxide(1159706-00-9)
• EPA Substance Registry System: [6S,9R,11R]-2',3',4',5,5',6,7,8,9,10-decahydro-2-([2-(4-fluorophenyl)-2-oxoethyl]carboxamido)-5'-(2,2,2-trifluoroethyl)-spiro[6,9-methanobenzocyclooctene-11,3'-[1,2,5]thiadiazole] 1',1'-dioxide(1159706-00-9)

Safety Data

• Hazardous Substances Data: 1159706-00-9(Hazardous Substances Data)

Upstream product

• 623577-15-1 (-)-[6S,9R,11R]-2',3',4',5,5',6,7,8,9,10-decahydro-2-carboxy-5'-(2,2,2-trifluoroethyl)-spiro[6,9-methanobenzocyclooctene-11,3'-[1,2,5]thiadiazole] 1',1'-dioxide 
• 456-00-8 2-amino-4'-fluoroacetophenone hydrochloride 

Relevant articles and documents

Novel orally bioavailable γ-secretase inhibitors with excellent in vivo activity

The development of potent γ-secretase inhibitors having substituted heterocycles attached to a benzobicyclo[4.2.1]nonane core is described. This work led to the identification of [6S,9R,11R]-2′,3′,4′,5, 5′,6,7,8,9,10-decahydro-2-(5-(4-fluorophenyl)-1-methylpyrazol-3-yl) -5′-(2,2,2-trifluoroethyl)spiro[6,9-methanobenzocyclooctene-11, 3′-[1,2,5]thiadiazole] 1′,1′-dioxide (16), which has excellent in vitro potency (0.06 nM) and which reduced amyloid-β in APP-YAC mice with an ED50 of 1 mg/kg (po). 16 had a good pharmacokinetic profile in three preclinical species.